<DOC>
	<DOCNO>NCT00983996</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's alendronate sodium 10 mg tablet Merck 's Fosamax 10 mg tablet follow single , oral 40 mg ( 4 x 10 mg ) dose administration fasting condition .</brief_summary>
	<brief_title>Fasting Study Alendronate Sodium Tablets ( 10 mg ) Fosamax Tablets ( 10 mg )</brief_title>
	<detailed_description />
	<mesh_term>Alendronate</mesh_term>
	<criteria>healthy , adult subject , 18 year older able swallow medication institutionalized subject history significant disease use prescription OTC medication within 14 day start study receive investigational product within 30 day prior start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>